237 related articles for article (PubMed ID: 27782699)
21. Effect of calculation method on kidney dosimetry in
Heikkonen J; Mäenpää H; Hippeläinen E; Reijonen V; Tenhunen M
Acta Oncol; 2016; 55(9-10):1069-1076. PubMed ID: 27219529
[TBL] [Abstract][Full Text] [Related]
22. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.
Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O
J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868
[TBL] [Abstract][Full Text] [Related]
23. Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation.
Dewaraja YK; Wilderman SJ; Ljungberg M; Koral KF; Zasadny K; Kaminiski MS
J Nucl Med; 2005 May; 46(5):840-9. PubMed ID: 15872359
[TBL] [Abstract][Full Text] [Related]
24. A Pipeline for Automated Voxel Dosimetry: Application in Patients with Multi-SPECT/CT Imaging After
Dewaraja YK; Mirando DM; Peterson AB; Niedbala J; Millet JD; Mikell JK; Frey KA; Wong KK; Wilderman SJ; Nelson AS
J Nucl Med; 2022 Nov; 63(11):1665-1672. PubMed ID: 35422445
[TBL] [Abstract][Full Text] [Related]
25. Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project.
Taprogge J; Vergara-Gil A; Leek F; Abreu C; Vávrová L; Carnegie-Peake L; Schumann S; Eberlein U; Lassmann M; Schurrat T; Luster M; Verburg FA; Vallot D; Vija L; Courbon F; Newbold K; Bardiès M; Flux G
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3225-3234. PubMed ID: 37300572
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the dosimetry approaches in ablation treatment of thyroid cancer.
Alan Selcuk N; Toklu T; Beykan S; Karaaslan SI
J Appl Clin Med Phys; 2018 Jul; 19(4):134-140. PubMed ID: 29858536
[TBL] [Abstract][Full Text] [Related]
27. I-131 SPECT/CT elucidates cryptic findings on planar whole-body scans and can reduce needless therapy with I-131 in post-thyroidectomy thyroid cancer patients.
Blum M; Tiu S; Chu M; Goel S; Friedman K
Thyroid; 2011 Nov; 21(11):1235-47. PubMed ID: 22007920
[TBL] [Abstract][Full Text] [Related]
28. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
[TBL] [Abstract][Full Text] [Related]
29. Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.
Koral KF; Dewaraja Y; Li J; Barrett CL; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
J Nucl Med; 2000 Sep; 41(9):1579-86. PubMed ID: 10994741
[TBL] [Abstract][Full Text] [Related]
30. 3D calculation of absorbed dose for 131I-targeted radiotherapy: a Monte Carlo study.
Saeedzadeh E; Sarkar S; Abbaspour Tehrani-Fard A; Ay MR; Khosravi HR; Loudos G
Radiat Prot Dosimetry; 2012 Jul; 150(3):298-305. PubMed ID: 22069233
[TBL] [Abstract][Full Text] [Related]
31. Dependency of the remnant
Mínguez P; Genollá J; Domínguez M; Expósito A; Santos B; Rodeño E
Phys Med; 2021 Aug; 88():45-52. PubMed ID: 34175746
[TBL] [Abstract][Full Text] [Related]
32. Validation of a Simple Thyroid Cancer Dosimetry Model Based on the Fractional Whole-Body Retention at 48 Hours Post-Administration of (131)I.
Atkins F; Van Nostrand D; Moreau S; Burman K; Wartofsky L
Thyroid; 2015 Dec; 25(12):1347-50. PubMed ID: 26357962
[TBL] [Abstract][Full Text] [Related]
33. Voxel-Based Dosimetry of Iron Oxide Nanoparticle-Conjugated
Gupta A; Shin JH; Lee MS; Park JY; Kim K; Kim JH; Suh M; Park CR; Kim YJ; Song MG; Jeong JM; Lee DS; Lee YS; Lee JS
Mol Pharm; 2019 Apr; 16(4):1498-1506. PubMed ID: 30821463
[TBL] [Abstract][Full Text] [Related]
34. Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery.
Samuel AM; Rajashekharrao B
J Nucl Med; 1994 Dec; 35(12):1944-50. PubMed ID: 7989975
[TBL] [Abstract][Full Text] [Related]
35. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry.
Prideaux AR; Song H; Hobbs RF; He B; Frey EC; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2007 Jun; 48(6):1008-16. PubMed ID: 17504874
[TBL] [Abstract][Full Text] [Related]
36. Calculation of Blood Dose in Patients Treated With 131I Using MIRD, Imaging, and Blood Sampling Methods.
Piruzan E; Haghighatafshar M; Faghihi R; Entezarmahdi SM
Medicine (Baltimore); 2016 Mar; 95(11):e3154. PubMed ID: 26986171
[TBL] [Abstract][Full Text] [Related]
37. Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal.
Vaiano A; Claudio Traino A; Boni G; Grosso M; Lazzeri P; Colato C; Davì MV; Francia G; Lazzeri M; Mariani G; Ferdeghini M
Nucl Med Commun; 2007 Mar; 28(3):215-23. PubMed ID: 17264781
[TBL] [Abstract][Full Text] [Related]
38. Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies.
Hartung-Knemeyer V; Nagarajah J; Jentzen W; Ruhlmann M; Freudenberg LS; Stahl AR; Bockisch A; Rosenbaum-Krumme SJ
Ann Nucl Med; 2012 Nov; 26(9):723-9. PubMed ID: 22802008
[TBL] [Abstract][Full Text] [Related]
39. Disseminated bone metastases from occult thyroid cancer effectively treated with debulking surgery and a single dosimetry-guided administration of radioiodine.
Borsò E; Boni G; Mazzarri S; Cocciaro A; Gambacciani C; Traino AC; Manca G; Grosso M; Scatena C; Ortenzi V; Vannozzi R; Marzola MC; Rubello D; Mariani G
Rev Esp Med Nucl Imagen Mol; 2015; 34(2):111-5. PubMed ID: 25455505
[TBL] [Abstract][Full Text] [Related]
40. Investigation of post-therapeutic image-based thyroid dosimetry using quantitative SPECT/CT, iodine biokinetics, and the MIRD's voxel S values in Graves' disease.
Fujita N; Koshiba Y; Abe S; Kato K
EJNMMI Phys; 2020 Jan; 7(1):6. PubMed ID: 31993828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
